If you are interested on healthcare research and new advances.

1. Gl bal Clinical Trials
HEALTH NEWS
“In a clinical research
study, doctors and
nurses evaluate how a
particular medication
works in the treatment
of a disease or condi-
tion. Before any new
medication can be ap-
proved, a clinical re-
search study must be
conducted. Without
them, we would have
no new treatment op-
tions”
In This Issue
 Why participate in a clinical
research?
 Involuntary movements
known as Tardive Dyskinesia
 Want to know more about
how far is your Alzheimer’s?
 Teen Schizophrenia new
options.
 Irritable bowel syndrome
Would you like to learn more
about your health condition?
Every day thousands of people like you take part in clini-
cal research studies. When you participate in our compensated
clinical trials, you are helping find new medical treatments. Addi-
tionally you are contributing to advancing research, which may
improve the future options of different conditions and some of
these are currently incurable diseases.
ALZHEIMER’S STUDY
Alzheimer’s disease has long affected many people worldwide. In the
US alone one in nine Americans over the age of 65 are diagnosed with
this disease. Global Clinical Trials has joined the fight to treat this dis-
ease through its cooperation in the STEADFAST Study. The placebo-
controlled study adds on to patients’ normal, day-to-day medication
with new, currently investigated medications to treat mild Alzheimer’s
disease. Participants in the STEADFAST study may receive azeliragon,
which may be effective at slowing the progression of Alzheimer’s dis-
ease. Participating in these studies helps to advance research, which
may help the future treatment of this currently incurable disease.
September—October 2015
Because success taste better when we work together.

2. Adolescent Schizophrenia
The Illuminate-301 study aims to find a new treatment for teenagers be-
tween the ages of 13-17 managing Schizophrenia symptoms.
Teen schizophrenia treatments are limited due to current medications that
only have been approved in adults. Further testing must be evaluated for
the drug to be extended to teens.
The Illuminate-301 study is trying to expand the approval by measuring
the safety and effectiveness of the study medication (lurasidone) in treat-
ing schizophrenia in teenagers.
Interested teens must first go through a screening process to determine
whether they meet the requirements to join this clinical research study.
The qualifications may be reviewed by contacting Global Clinical Trials.
IBS (Irritable Bowel Syndrome)
IBS affects between 25 and 45 million people in the United States (10
to 15% of the population). About 2 in 3 IBS sufferers are female.
About 1 in 3 IBS sufferers are male. IBS affects people of all ages,
even children.
The exact cause of IBS is not known. Symptoms may result from a
disturbance in the way the gut, brain, and nervous system interact.
This can cause changes in normal bowel movement and sensation.
IBS is unpredictable. Symptoms vary and are sometimes contradicto-
ry. Diarrhea can alternate with constipation. Long-term symptoms can
disrupt personal and professional activities, and limit individual poten-
tial.
Although IBS is common in the general population, few seek medical
care for their symptoms.
Tardive
Dyskinesia
Global Clinical Trials is con-
ducting a clinical study to
treat Tardive Dyskinesia, a
disorder that consists of
Involuntary Movements
that affect as many as
500,000 people in the Unit-
ed States alone. Currently
two clinical research stud-
ies are being offered to
help work towards treat-
ment for this disorder.
Both Studies are working
towards developing treat-
ment for this currently un-
treatable disorder through
placebo-controlled methods
that place the safety of pa-
tients and efficacy in treat-
ment above all else – an
effort that Global Clinical
Trials is proud to be a part
of.
For more information contact:
Monica Cuitiva
Community Outreach/Marketing Director
Follow us https://www.facebook.com/
globalclinicaltrials
monica@globalclinicaltrials.org
Ph: 949 660 1523
Cell: 714 561 6366